Piper Sandler Downgrades Traeger to Neutral, Lowers Price Target to $4

Piper Sandler analyst Peter Keith downgrades Traeger (NYSE:COOK) from Overweight to Neutral and lowers the price target from $6 to $4.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Piper Sandler analyst Peter Keith downgrades Traeger (NYSE:COOK) from Overweight to Neutral and lowers the price target from $6 to $4.

Keybanc Maintains Overweight on Materion, Raises Price Target to $85

By Benzinga Newsdesk

Today, 5:37 PM

Keybanc analyst Philip Gibbs maintains Materion (NYSE:MTRN) with a Overweight and raises the price target from $82 to $85.

MTRN

HC Wainwright Reiterates On Pluristem After Encouraging Initial Data

By Vandana Singh

Today, 5:37 PM

Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture surgery.

PSTI

Read Why UBS Is Bullish On This E-Commerce Giant, Sees 37% Upside

By Anusuya Lahiri

Today, 5:37 PM

UBS analyst Kunal Madhukar assumed coverage of Amazon.com Inc (NASDAQ:AMZN) with a Buy rating and $4,700 price target, implying a 36.5% upside. Amazon…

AMZN

CytomX Therapeutics Announces Preliminary Results For Ongoing Phase 2 Expansion Study Of CX-2029, A First-in-Class Antibody-Drug Conjugate Candidate Targeting The Transferrin Receptor, CD71

By Benzinga Newsdesk

Today, 5:37 PM

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated therapeutics, today announced preliminary Phase 2 results in patients with either advanced squamous non-small cell lung cancer

CTMX

Piper Sandler Downgrades Traeger to Neutral, Lowers Price Target to $4

Related Posts

Keybanc Maintains Overweight on Materion, Raises Price Target to $85

HC Wainwright Reiterates On Pluristem After Encouraging Initial Data

Read Why UBS Is Bullish On This E-Commerce Giant, Sees 37% Upside

CytomX Therapeutics Announces Preliminary Results For Ongoing Phase 2 Expansion Study Of CX-2029, A First-in-Class Antibody-Drug Conjugate Candidate Targeting The Transferrin Receptor, CD71